<DOC>
	<DOC>NCT00256399</DOC>
	<brief_summary>Uroxatral (alfuzosin) may not only help BPH symptoms but may also improve sexual function in males with BPH and ED.</brief_summary>
	<brief_title>Uroxatral in Men With Benign Prostate Hypertrophy (BPH) and Erectile Dysfunction (ED)</brief_title>
	<detailed_description>The study will consist of a 30 day screening/washout phase at the end of which qualified subjects will be assigned to alfuzosin 10 mg tablets once a day. Subjects will be treated for 90 days. The total duration of the study will be 120 days.</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Males 4575 years of age Confirmed diagnosis of BPH/lower urinary tract symptoms (LUTS) and ED Men with steady partner and who agree to attempt sex once a week. Prostate cancer Prostatitis Penile disease Cardiac comorbidity Preexisting comorbid conditions History of sensitivity to the drug or similar drugs Enrollment in another clinical trial Impaired hepatic function Impaired renal function Mental conditions rendering subject unable to understand the study Subjects not likely to comply with protocol</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>